Actinium announces expansion of its R&D team and facilities to accelerate research programs focused on solid tumors and novel combinations with checkpoint inhibitors and radioconjugates

NEW YORK, September 27, 2021 / PRNewswire / – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiation therapy for patients with unmet needs, today announced several updates on its R&D capabilities. Actinium recently completed the expansion of its New York City research facilities based to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to study novel combinations of radiotherapy with checkpoint inhibitors. Actinium has more than doubled the footprint of its laboratories and extended its R&D capabilities. In addition to infrastructure, Actinium has expanded its R&D team to include scientists with expertise in cancer biology, immunology, radiation science and chemistry, including the appointment of Helen Kotanides, Ph.D., as Vice President, Translational Research and Preclinical Development and Monideepa Roy, Ph.D., as Vice-President, Corporate Development – R&D to his R&D management team.

Sandesh Seth, Chairman and CEO of Actinium, said: “I am delighted to announce the arrival of Dr. Kotanides and Dr. Roy to the Actinium R&D leadership team. Targeted radiotherapy is rapidly establishing itself as a differentiated therapeutic modality capable of producing results where other approaches have. We intend to continue to be at the forefront of innovation in the field, leveraging our understanding in-depth understanding of radioconjugate behavior, the AWE technology platform, clinical experience and supply chain, and most importantly our team of leading scientists and clinicians to achieve our goals focused on tumor indications solid and new combinations of targeted radiotherapy. The addition of Dr Kotanides and Dr Roy to senior R&D positions and the expansion of our R&D capabilities allow us to significantly accelerate these efforts. We look forward to showcasing our expanded R&D capabilities in the near future and highlighting new initiatives and programs to complement our targ at an advanced stage clinical radiotherapy program led by Iomab-B, whose recruitment we recently finalized for phase 3 pivot SIERRA trial.”

Dr Kotanides joins Actinium after a distinguished career with continuous succession through several positions culminating as Senior Research Advisor, Cancer Immunobiology. Dr Kotanides brings nearly 25 years of R&D experience to ImClone Systems, then Eli Lilly, with a focus on preclinical discovery and biologic drug development in oncology. She has extensive knowledge and experience in cancer biology and immunotherapy, including target discovery and testing, development and advancement of biologics, immune checkpoint therapies and targeted therapies. . As a result, Dr Kotanides has conducted several preclinical programs towards successful IND cases. Dr. Kotanides obtained her doctorate. in molecular biology and biochemistry of State University of New York To Stony stream, his master’s degree in biology of New York University and his bachelor’s degree in biology from Clark University.

Dr Roy is a scientist-entrepreneur whose background includes a tenure as CEO of an early stage oncology drug development company and nearly a decade of academic experience that includes training and experience in work at Harvard Medical School/ Brigham and Women’s Hospital. Dr Roy joins Actinium after working at Akamara Therapeutics, where she most recently served as Vice President, Business Development and Operations. As a founding member and interim CEO of Akamara, she played a critical role in recruiting a leadership team, establishing corporate and corporate R&D strategy, operational execution and growing the global team from 4 to 40. During her tenure at Akamara, she contributed to partnership / collaboration efforts, development of portfolio strategies, evaluation of technology platforms, oversight of research activities. to support IND filings, lead regulatory preparation and submissions, and work to generate and secure intellectual property. Prior to Akamara, she was Director of Research and Development at Invictus Oncology Pvt. Ltd., a drug discovery company developing novel I / O and conjugate antibody therapies. Here, she co-led technology licensing at Brigham and Women’s Hospital, raised Series A funding, established the company’s strategy around a B-cell immunotherapy platform, and established a international research capacity to advance the technologies of the company. In addition, she established a KOL network and identified and evaluated supramolecular platform technologies. Prior to working in industry, Dr Roy was a lecturer at Harvard University, was a special member of the Leukemia & Lymphoma Society and researcher in the pathology department of Brigham and Women’s Hospital /Harvard Medical School. Dr. Roy obtained her doctorate. in Molecular Biology from Jawaharlal Nehru University, his Masters in Biophysics and Molecular Biology from the University College of Science, Calcutta and his bachelor’s degree in human physiology from the Presidential College, Calcutta.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiation therapies to deliver anticancer radiation with precision at the cellular level to treat patients whose unmet needs are not met by traditional cancer therapies. Actinium’s current clinical pipeline is driven by ARCs or antibody radiation conjugates that are applied to targeted conditioning, intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a transplant. bone marrow or bone marrow, gene therapy or adoption of cell therapy (ACT) such as CAR-T to enable the transplantation of these transplanted cells with minimal toxicities. Actinium’s targeted conditioning ARCs aim to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing untargeted chemotherapy that is currently used for conditioning in standard practice. Our lead product candidate, apamistamab I-131 (Iomab-B) has been studied in several hundred patients, including in the recently fully recruited 150-patient pivotal phase 3 study of Iomab-B for treatment relapsing or refractory acute myeloid leukemia in the elderly (SIERRA) test for BMT conditioning. Iomab-ACT, low dose apamistamab I-131 is being investigated as a targeted conditioning agent in a phase 1 study with CD19 CAR T cell therapy with Memorial Sloan Kettering Cancer Center. In addition, we are leaders in the field of alpha-actinium-225 therapies. Actimab-A, our clinical stage CD33 targeting ARC alpha therapy, has been studied in nearly 150 patients, including our ongoing combination trials with lifesaving chemotherapy CLAG-M and targeted therapy Bcl-2 venetoclax. Our exclusive AWE (Antibody Warhead Enabling) technological platform is the basis of our clinical programs. This is where our intellectual property portfolio of more than 160 patents, our know-how, our collective research and our expertise in the field are used to build and study new ARCs and combinations of ARCs in order to strengthen our pipeline for strategic purposes. Our AWE technology platform is currently in use in a collaborative research partnership with Astellas Pharma, Inc. Website:

Forward-looking statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe harbor” provisions of the Securities Litigation Reform Act 1995 regarding future events or the future financial performance of the Company, that the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including the risks and uncertainties associated with the results of preliminary studies. varying end results, estimates of potential markets for drugs in development, clinical trials, actions of the FDA and other government agencies, regulatory approvals, answers to regulatory questions, market demand and l ‘acceptance of Actinium’s products and services, the performance of clinical research organizations and other risks detailed from time to time in documents filed by Actinium with the Securities and Exchange Commission (the “SEC”), including, without limitation, its most recent annual report on Form 10-K, subsequent quarterly reports on Forms 10-Q and 8-K, each as amended and supplemented by from time to time.

Hans vitzthum
LifeSci Advisors, LLC
[email protected]
(617) 430-7578

SOURCE Actinium Pharmaceuticals, Inc.

Related links

About Hector Hedgepeth

Check Also

Dr. Vizarath Rasool Khan’s free mega medical camp ended successfully

Hyderabad: Dr. Vizarath Rasool Khan’s Free Mega Medical Camp at Shadan Hospital successfully ended on …

Leave a Reply

Your email address will not be published.